LGT Capital Partners LTD. Invests $14.76 Million in IQVIA Holdings Inc. (NYSE:IQV)

LGT Capital Partners LTD. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 75,100 shares of the medical research company’s stock, valued at approximately $14,758,000.

Other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the 3rd quarter valued at approximately $27,000. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth approximately $33,000. Avior Wealth Management LLC grew its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares in the last quarter. Assetmark Inc. grew its holdings in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of IQVIA during the 3rd quarter worth approximately $57,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Up 3.4 %

NYSE:IQV opened at $191.69 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $33.80 billion, a price-to-earnings ratio of 25.56, a PEG ratio of 1.99 and a beta of 1.50. The stock has a 50-day moving average price of $197.79 and a two-hundred day moving average price of $212.87. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $261.72.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

IQV has been the topic of several recent research reports. Morgan Stanley lifted their price objective on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Robert W. Baird decreased their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Bank of America decreased their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. UBS Group decreased their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.